Paper2Agent-generated agents used AlphaGenome to prioritize GPR137 as the top predicted gene affected by psoriasis-associated variant rs887314 in CD4+ T cells, then integrated that prediction with existing MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq data. A cross-screen correlation of gene-expression signatures supported GPR137 as the probable causal gene under stimulated conditions (Spearman rho 0.613 at 8 h and 0.630 at 48 h; FDR < 0.05), but not at rest. The paper presents this as activation-dependent computational evidence.
Technology: Paper2Agent-generated AlphaGenome, MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq agents, coordinated through an AI co-scientist
Family AI Co-Scientist: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Paper2Agent-generated agents used AlphaGenome to prioritize GPR137 as the top predicted gene affected by psoriasis-associated variant rs887314 in CD4+ T cells, then integrated that prediction with existing MPRA-coupled scCRISPRi and CD4+ T-cell Perturb-seq data.
- Still unknown: The analysis reuses existing published datasets and does not report new wet-lab experiments for this psoriasis case. AlphaGenome supplied a model prediction; cross-dataset signature correlation supports, but does not establish, causal biology. The GPR137 concordance was significant only after stimulation, and the authors describe it as probable/activation-dependent. A human researcher selected which AI-proposed strategy to run. Primary paper source checked; no independent replication assessed.
- AI role: The AlphaGenome paper agent scored and ranked candidate genes at rs887314. Under human-in-the-loop supervision, the AI co-scientist inspected two other paper agents' datasets, proposed ten validation strategies, and the researcher selected signature-correlation analysis. The resulting cross-screen, cross-modality analysis found significant concordance for GPR137 only under stimulated conditions.
Evidence sources: https://www.nature.com/articles/s41586-026-11044-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A precomputed database of predicted molecular effects for about 9 billion possible single-letter changes in the human genome, generated by AlphaGenome. Researchers can access it free through a portal and API. The predictions are a research tool, do not replace experiments, and are not validated for clinical use.
Technology: AlphaGenome, AlphaGenome Variant Impact (AVI)
Family AlphaGenome: profile · models page
Publication: Announcement only · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: retrospective or benchmark
- Tested: Validation described is the company's own testing of the AlphaGenome Variant Impact score on pathogenicity benchmarks, plus case studies: a DNM1 variant prioritized with GREGoR and 22% more non-coding associations in UK Biobank.
- Still unknown: The page does not detail how individual predictions were checked; AlphaGenome is not validated or approved for clinical use.
- AI role: AlphaGenome predicted variant effects across cell types and tissues; these were precomputed for about 9 billion variants and combined with AlphaMissense into a single score.
Evidence sources: https://deepmind.google/blog/alphagenome-atlas-a-predictive-map-of-every-possible-dna-letter-change-in-the-human-genome/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The model reads sequences up to 1 million base pairs and predicts thousands of gene-regulation properties at single-letter resolution. It outperformed the best external models in 22 of 24 sequence evaluations and matched or outperformed the best in 24 of 26 variant evaluations. Stated limits: distant regulatory elements; not validated for personal genomes or clinical use.
Technology: AlphaGenome
Family AlphaGenome: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: AlphaGenome was evaluated on sequence and variant-effect benchmarks against external models, outperforming in 22 of 24 and matching or exceeding in 24 of 26 evaluations, plus a TAL1 case study.
- Still unknown: The source states it is not validated for personal genomes or clinical use, distant regulatory elements remain a challenge, and cell-specific patterns need improvement.
- AI role: A model takes up to 1 million DNA base pairs and predicts thousands of genomic tracks and variant effects.
Evidence sources: https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome/ · https://www.biorxiv.org/content/10.1101/2025.06.25.661532
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.